TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06413602

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypoxia
Description: During AIH, the participant will be equipped with a non-rebreathing face mask, and provided with the AIH intervention. The AIH intervention involves alternating breathing cycles. One cycle involves breathing air with lower oxygen concentration (9-10% oxygen) for 30 and 90 seconds, followed by breathing normal room air (21% oxygen) for a similar duration. This cycle is repeated 15 times in one session. Blood oxygen and heart rate are monitored throughout.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypoxia
Description: During AIH, the participant will be equipped with a non-rebreathing face mask, and provided with the AIH intervention. The AIH intervention involves alternating breathing cycles. One cycle involves breathing air with lower oxygen concentration (9-10% oxygen) for 30 and 90 seconds, followed by breathing normal room air (21% oxygen) for a similar duration. This cycle is repeated 15 times in one session. Blood oxygen and heart rate are monitored throughout.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: During NMES, participants will receive electrical stimulation to the common peroneal nerve. Stimulation will be done with a 50% duty cycle, duration of 0.5-1ms for each pulse and a frequency 25-40 Hz. The stimulus intensity will be adjusted to produce approximately 50% of the maximum M-wave (compound muscle action potential) for each participant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: During NMES, participants will receive electrical stimulation to the common peroneal nerve. Stimulation will be done with a 50% duty cycle, duration of 0.5-1ms for each pulse and a frequency 25-40 Hz. The stimulus intensity will be adjusted to produce approximately 50% of the maximum M-wave (compound muscle action potential) for each participant.
Study: NCT06525415

Intervention type: DIAGNOSTIC_TEST
Intervention: DCE MRI
Description: the recruited patients should complete pre- and post-operative DCE MRI workshops
Study: NCT06240052

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conditioning and active avoidance paradigm (CAAP)
Description: On day 1 subjects will undergo image viewing, fear conditioning, and avoidance learning. Subjects will be instructed to passively view the images from 3 categories on the screen, with 2 of the 3 categories being paired with a mild shock to the subjects' foot. Then they will see a picture of a button on the screen together with all three categories. If they press the button, they may prevent the shock from occurring. Pressing the button for one of the conditioned categories will prevent the shock from happening. Pressing the button to the other conditioned cue will not prevent the shock .Pressing the button to the third category does nothing. On day 2, subjects will be given $5 and will be told that they can press a button to avoid a shock. The number of times the button was pressed will be counted and if it is less than the number by another randomly selected participant then the participant will get to keep the money.
Study: NCT06429150

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T cells
Description: Infusion of multi-CAR-T cells
Study: NCT05036174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 5%
Description: Diphenhydramine 5% ointment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to diphenhydramine 5% ointment
Study: NCT05979740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin and Toripalimab
Description: Each patient received RC48 injection \[2.0 mg/kg, Q2W, iv\] and Toripalimab injection \[3mg/kg, Q2W, iv\] for 1\~2 cycles, and Radiotherapy radiotherapy at the second or third cycle. The total dose of bladder irradiation field was greater than 50Gy (about 30 times), and the safety monitoring of the subjects was conducted within 28 days after receiving the study drug treatment for the first time.
Study: NCT05246917

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Handsewn anastomosis
Description: To perform hand sewn anastomosis (either end to end or Kono-s) during the reconstruction face of ileocolic resection
Study: NCT05421741

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic coated intramedullary Nail
Description: Antibiotic coated intramedullary nail:~A mixture of 40gm bag of acrylic cement, antibiotic powder (Vancomycin 2gm) and 560mg gentamicin liquid. The intramedullary is coated with the mixture using a cement gun tube.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Intramedullary Nail
Description: Standard Intramedullary Nail
Study: NCT06223334

Intervention type: OTHER
Intervention: No intervention
Description: observational study to evaluate the different clinical and etiological patterns of epileptic syndromes in infants and early childhood.

Intervention type: OTHER
Intervention: No intervention
Description: observational study to evaluate the different clinical and etiological patterns of epileptic syndromes in infants and early childhood.

Intervention type: OTHER
Intervention: No intervention
Description: observational study to evaluate the different clinical and etiological patterns of epileptic syndromes in infants and early childhood.

Intervention type: OTHER
Intervention: No intervention
Description: observational study to evaluate the different clinical and etiological patterns of epileptic syndromes in infants and early childhood.

Intervention type: OTHER
Intervention: No intervention
Description: observational study to evaluate the different clinical and etiological patterns of epileptic syndromes in infants and early childhood.

Intervention type: OTHER
Intervention: No intervention
Description: observational study to evaluate the different clinical and etiological patterns of epileptic syndromes in infants and early childhood.
Study: NCT05718947

Intervention type: DIAGNOSTIC_TEST
Intervention: Brain MRI (3T, 7T, 9.4T)
Description: All patients will undergo anatomical brain imaging on a 3T, 7T and 9.4T MRI scanner within the same day at baseline and again 6 months later. An optimized protocol for every separate field strength will be run. Sequences will include at least T1-weighted, T2\*-weighted and a T2 SPACE or FLAIR sequence. No intravenous contrast will be used.
Study: NCT05933746

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Hygiene Intervention
Description: This 1-hour on-line intervention presents three sleep hygiene modules, selected randomly from among these six: establishing a bedtime routine, optimizing sleep environment, implementing a sleep schedule, bedtime relaxation, nutrition choices, and exercise habits.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-behavioral Sleep Education
Description: 1-hour on-line set of three modules that cover non-skill (non-hygiene) educational topics (sleep research, sleep stages, dreams). This control condition equates for engagement rationale.
Study: NCT06333249

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV2tYF-GRK1-RPGR
Description: Adeno-associated virus vector expressing a human RPGR gene

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV2tYF-GRK1-RPGR
Description: Adeno-associated virus vector expressing a human RPGR gene
Study: NCT04309292

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic food supplement
Description: Darmocare Pre = trade name Gut microbiome modulator

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Protein supplement
Description: commercially available protein supplementation with high leucine content

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplement
Description: commercially available protein supplementation with high leucine content

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltrodextrin (placebo)
Description: Starchy substance
Study: NCT04991870

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cord Blood-derived Expanded Allogeneic Natural Killer Cells
Description: Given CB-NK-TGF-betaR2-/NR3C1- intratumorally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cord Blood-derived Expanded Allogeneic Natural Killer Cells
Description: Given CB-NK-TGF-betaR2-/NR3C1- intratumorally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo surgical resection
Study: NCT05696483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLX-07010 Active
Description: 25 and 75 mg capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OLX-07010 Placebo
Description: 25 and 75 mg capsules
Study: NCT04951115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC = 5-6 mg/mL per min on Day 1 of each 21-day cycle, for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75-80 mg/m2 on Day 1 of each 21-day cycle, for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 80-100 mg/m2 on Day 1, Day 2, and Day 3 of each 21-day cycle, for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500 mg on Day 1 of each 21-day cycle, for 4 cycles. Following this, 1500 mg once every 4 weeks until disease progression

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: 6 Gy of radiotherapy targeting multiple sites of intrathoracic disease on Days 1-5 of cycle 1.
Study: NCT05227456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel 68mg implant
Description: Implant will be inserted

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Etonogestrel 68mg implant
Description: Implant will be inserted
Study: NCT04895254

Intervention type: DEVICE
Intervention: Diagnostic colonoscopy
Description: The feasibility of the motorized spiral enteroscope to achieve cecum intubation in difficult colons.

Intervention type: PROCEDURE
Intervention: Therapeutic colonoscopy
Description: The feasibility of the motorized spiral enteroscope for performing interventions such as polypectomy
Study: NCT06381804

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: shotblocker
Description: shotblocker device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: palm stimulator
Description: palm stimulator
Study: NCT04647370

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: remote ischemic preconditioning
Description: 3 cycles of 5-minutes inflation of a blood pressure cuff to 200mmHg (or at least to a pressure 50mm Hg higher than the systolic arterial pressure) to one upper arm, followed by5-minutes reperfusion with the cuff deflated

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham remote ischemic preconditioning
Description: 3cycles of upper limb pseudo ischemia (low pressure, 5-minutes blood pressure cuff inflation to a pressure of 20 mm Hg and 5-minutes cuff deflation).
Study: NCT04796714

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Double antiplatelet therapy
Description: One sachet of aspirin 160 mg and one tablet of clopidogrel 75 mg per day.during 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: One sachet of aspirin 160 mg per day during 3 months

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain MRI
Description: Two cerebral Magnetic Resonance Imaging (MRI) examinations will be carried out (D0 and D90).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Brain MRI
Description: Two cerebral Magnetic Resonance Imaging (MRI) examinations will be carried out (D0 and D90).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurological tests
Description: Neurological assessment with the implementation of the modified rankin, National Institute of Health Stroke Score (NIHSS), and Montreal Cognitive Assessment (MoCA) tests (D1 and M3)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Neurological tests
Description: Neurological assessment with the implementation of the modified rankin, National Institute of Health Stroke Score (NIHSS), and Montreal Cognitive Assessment (MoCA) tests (D1 and M3)
Study: NCT05998369

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowered Relief for Youth
Description: The Empowered Relief for Youth is a 90-minute class that provides pain science education, as well as cognitive, emotional, and physiologic self-regulation skills for youth with chronic pain. Youth will also develop a personalized plan to use the acquired skills daily. Participants will receive an audio file (Relaxation Response) post-class. The class provides patients rapid access to actionable skills for symptom management and pain relief.
Study: NCT06107777

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacopuncture
Description: Pharmacopuncture is a treatment that combines 2 of the most frequented Korean medicine treatment methods - traditional acupuncture and herbal medicine - by injecting herbal medicine extract at acupoints.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Korean medical treatment
Description: acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Korean medical treatment
Description: acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
Study: NCT05198817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-2002 injection、Camrelizumab for Injection, SHR-1316 injection, SHR-1701 injection
Description: Firstly Dose Escalation and Dose Expansion of SHR-2002 injection monotherapy should be conducted. After RP2D and MTD of the SHR-2002 injection monotherapy were confirmed, Dose Escalation, Dose Expansion and Efficacy Expansion of SHR-2002 injection in combination with other anti-cancer treatment would be completed, including Camrelizumab for Injection, or SHR-1316 injection, or SHR-1701 injection.
Study: NCT06340022

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Children's Fear Survey Schedule-Dental Subscale (CFSS-DS) scale
Description: Children's Fear Survey Schedule-Dental Subscale (CFSS-DS) scale was applied to determine the anxiety level before the procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Children's Fear Survey Schedule-Dental Subscale (CFSS-DS) scale
Description: Children's Fear Survey Schedule-Dental Subscale (CFSS-DS) scale was applied to determine the anxiety level before the procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Face Image Scale (FIS) scoring system
Description: Face Image Scale (FIS) scoring system (1= not afraid at all, 2= very little afraid, 3= afraid, 4= quite afraid, 5= very much afraid) was used to determine the anxiety level before starting anesthesia and after the anesthesia.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Face Image Scale (FIS) scoring system
Description: Face Image Scale (FIS) scoring system (1= not afraid at all, 2= very little afraid, 3= afraid, 4= quite afraid, 5= very much afraid) was used to determine the anxiety level before starting anesthesia and after the anesthesia.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS)
Description: In the Visual Analogue Scale (VAS), the patient was asked to rate the pain he/she felt during anesthesia on a 10 cm long ruler ranging from no pain=0 to unbearable pain=10.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS)
Description: In the Visual Analogue Scale (VAS), the patient was asked to rate the pain he/she felt during anesthesia on a 10 cm long ruler ranging from no pain=0 to unbearable pain=10.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pulse rate
Description: Before starting anesthesia and after the anesthesia the patient's pulse rate was measured and recorded with a pulse oximeter.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pulse rate
Description: Before starting anesthesia and after the anesthesia the patient's pulse rate was measured and recorded with a pulse oximeter.
Study: NCT06169202

Intervention type: DEVICE
Intervention: fruquintinib
Description: 4 mg orally once daily, D1-14, repeated every 3 weeks.

Intervention type: DRUG
Intervention: Irinotecan
Description: 180 mg/m2, IV, day 1, repeated every 3 weeks. (Note: If patient has UGT1A1\*28 and \*6 as pure or double heterozygous variants, irinotecan dose 150 mg/m2, IV, day 1, repeated every 3 weeks, with close clinical observation).

Intervention type: DRUG
Intervention: Capecitabine
Description: 1000 mg/m2 orally twice daily, D1-14, repeated every 3 weeks.
Study: NCT05809921

Intervention type: DRUG
Intervention: alteplase
Description: Intravenous thrombolysis with alteplase (0.9 mg/kg, maximum 90 mg) with 10% of the dose given as a bolus followed by an infusion lasting 60 minutes.

Intervention type: DRUG
Intervention: Alteplase + possible complementary IVT with tenecteplase
Description: Intravenous thrombolysis with alteplase (0.9 mg/kg, maximum 90 mg, with 10% of the dose given as a bolus followed by an infusion lasting 60 minutes) and depending on the MRI-2 results, an additional IVT with tenecteplase (0.25mg/kg, maximum 25 mg, with 100% of the dose given as a bolus) could be given in case of persistent occlusion and with no contraindication according to the study protocol.
Study: NCT05857735

Intervention type: OTHER
Intervention: Observational registry with no intervention.
Description: No intervention
Study: NCT06260566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: This is a phase 1 study of tolerance of a novel delivery method of oral NAC medication in infants with biliary atresia. The study consists of two parts:~* Administering applesauce alone (lead-in): In study days 1-2, infants will receive one infant spoon (approximately ½ teaspoon) of plain applesauce by mouth twice a day. If the infant tolerates 3-4 of 4 total doses without emesis, the infant will progress to the final two days of the study.~* Administering applesauce plus NAC (for infants who tolerate applesauce in study days 1-2): In study days 3-4, infants will receive an individualized dose of powdered oral NAC mixed into one infant spoon of applesauce by mouth twice a day for a maximum of four doses of NAC medication. 4 doses will be trialed: 150 mg/kg/day, 240 mg/kg/day, 330 mg/kg/day, and 420 mg/kg/day using BOIN study design for dose escalation.
Study: NCT04273607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous Heparin
Description: The intervention group will receive prophylactic heparin instead of standard of care therapeutic intravenous heparin
Study: NCT06019624

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Takes!
Description: Receipt of a fresh produce box, nutritional education and support in a 6 month program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Takes!
Description: Receipt of a fresh produce box, nutritional education and support in a 6 month program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Takes!
Description: Receipt of a fresh produce box, nutritional education and support in a 6 month program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Takes!
Description: Receipt of a fresh produce box, nutritional education and support in a 6 month program
Study: NCT05749146

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home Palliative Care
Description: Patients/caregivers will be cared for by an interdisciplinary team that includes a social worker, nurse, community health worker, nurse practitioner, and physician.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Palliative Care
Description: Patients/caregivers will be cared for by an interdisciplinary team that includes a social worker, nurse, community health worker, nurse practitioner, and physician.
Study: NCT06304103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AND017
Description: Administer AND017 once per day (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AND017
Description: Administer AND017 once per day (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AND017
Description: Administer AND017 once per day (QD)
Study: NCT06345716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracétamol tramadol
Description: Each patient received 1 tablet \* 2/day synalvic (325 mg of paracetamol + 37.5 mg of tramadol) for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracétamol cafeine
Description: Each patient received 1 tab \* 3/d stopalgic extra (65mgcaffeine+500mg paracetamol) for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Each patient received 1 tab \* 3 / d of placebo (flour) every day for 7 days
Study: NCT04319367

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigational Medicinal Product
Description: Recombinant human monoclonal antibody (mAb) or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Investigational Medicinal Product
Description: Recombinant human monoclonal antibody (mAb) or placebo
Study: NCT05095636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: oral Apatinib once everyday

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apatinib Mesylate
Description: oral Apatinib once everyday

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: intravenous camrelizumab 200mg once every two weeks
Study: NCT04870658

Intervention type: PROCEDURE
Intervention: Dental implant treatment
Description: Patients who receive one o more dental implant treatment to restore oral function.
Study: NCT05233865

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Water exercise
Description: Participants will be asked to sit and stand multiple times (before, immediately after, and 2 hours after a 15-minute walking session). The walking session will consist of 3 minutes of walking at a light intensity followed by 9 min of walking at a moderate intensity and a 3-minute cool down walking at a light intensity. This walking session will occur in a pool.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Land exercise
Description: Participants will be asked to sit and stand multiple times (before, immediately after, and 2 hours after a 15-minute walking session). The walking session will consist of 3 minutes of walking at a light intensity followed by 9 min of walking at a moderate intensity and a 3-minute cool down walking at a light intensity. This walking session will occur on land.
Study: NCT05685043

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: perfusion CT
Description: Patients are selected for thrombectomy based on perfusion CT criteria. When the results from the perfusion CT scan (analyzed by RAPID software) indicate a core infarct volume exceeding 70 ml in patients \< 80 years or 55 ml in patients \> 80 years, then treatment is limited to best medical treatment (intravenous fibrinolysis if applicable) and no mechanical thrombectomy will be performed. This is the current standard of care for patients treated more than 6 hour after onset.